Compare Abeona Therapeutics Inc (ABEO) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Texas Instruments Incorporated — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Texas Instruments Incorporated trades at $301.26 (market cap $266.93B). The key difference: Texas Instruments Incorporated is far larger — about 715× Abeona Therapeutics Inc's market cap, and Texas Instruments Incorporated pays a 1.94% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TXN | |
|---|---|---|
Market Cap | $373.32M | $266.93B |
Sector | Health | Technology |
52-Week High | $7.23 | $332.35 |
52-Week Low | $4.17 | $153.33 |
Enterprise Value | $228.22M | $275.88B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Texas Instruments (TXN) trades at $303.50, up 3.56% over 24 hours, with a bullish technical signal and strong profitability metrics including a 29.11% net income margin. Recent Q1 2026 earnings beat expectations, and the company announced a CFO transition with Julie Knecht set to succeed Rafael Lizardi in August 2026. Cash flow trends show improving operational performance, with 2025 operating cash flow at $7.15 billion.
The outlook remains positive with analyst consensus pointing to a $310.95 price target and 47.69% buy ratings. Key risks include elevated valuation ratios like a P/E of 51.88 and rising debt-to-asset ratio, now at 40.61% for 2025. Growth is supported by AI-driven demand in data centers, but investors should monitor execution on sequential revenue guidance and competitive pressures in the semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
